Allogeneic BAFF-based CAR T Cells for B Cell Cancers
Official title: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies
Funded at Luminary Therapeutics, INC. · NIH-11421504 · Data updated 2026-11-12
A new donor-derived CAR T cell therapy using BAFF ligands is being explored to treat B cell malignancies like mantle cell lymphoma, aiming for better persistence and easier access than current autologous treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Luminary Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | July 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $586,799 |
| NIH project number | 5R44CA278021-03 |
| Project ID | NIH-11421504 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with B cell malignancies, particularly mantle cell lymphoma, who could benefit from an allogeneic, BAFF-based CAR T cell therapy.
✕Less likely to help
Patients unlikely to benefit may include those with non-B cell malignancies or those who cannot receive allogeneic cell therapies due to contraindications.
What this research studies
This project proposes an off-the-shelf CAR T cell approach using BAFF ligand to target B cell cancers, aiming to reduce relapse and lower costs compared to patient-derived therapies. It plans to use an allogeneic gamma delta T cell platform to potentially improve safety and manufacturing efficiency. The research focuses on mantle cell lymphoma and the way BAFF receptor signaling might support memory formation and serial killing of cancer cells. If successful, it could offer patients a quicker, more scalable therapy option with equivalent or improved efficacy.
Why it matters
Potential benefit: If successful, patients could access an effective off-the-shelf CAR T therapy with potentially faster treatment and improved long-term disease control.
How similar studies have gone: Prior autologous CAR T therapies have shown durable remissions, but relapse and manufacturing challenges remain; this approach is exploratory and builds on existing CAR T concepts with a novel BAFF-based design.
Where this research is happening
-
Luminary Therapeutics, INC.
Minneapolis, United States Active
Researchers
- Principal investigator: Gibbons, Hunter Ramsdell — Luminary Therapeutics, INC.
- Study coordinator: Gibbons, Hunter Ramsdell
Related research
Other NIH-funded projects on the same topics.
-
Off-the-shelf BAFF-targeting CAR T for B‑cell cancers
An off-the-shelf CAR T-cell therapy that uses the BAFF ligand to target B‑cell cancers like mantle cell lymphoma.
-
A new CAR T cell therapy targeting ovarian cancer
This study is testing a new type of CAR T cell therapy for women with ovarian cancer that uses special immune cells to better target the cancer and includes a safety feature to help protect patients from side effects.
-
New CAR T-cell therapy targeting B cells for lupus treatment
This study is testing a new type of CAR T-cell therapy designed to help people with systemic lupus erythematosus (SLE) by targeting and removing the harmful B cells that contribute to the disease, with the hope of improving treatment outcomes and safety.
-
New CAR T cell therapy for B cell cancers
This study is testing a new treatment using special immune cells to help people with mantle cell lymphoma, aiming to make the therapy work better and last longer by using a unique approach to boost the immune response against the cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.